ESJTI

EuroScience Journal of Technological Innovation (ESJTI)

An International Open Access, Peer-Reviewed, Refereed Journal

Current Trends in Cancer Research and Drug Development

[1]Muhammad Akram, [2] Hamza Khalifa Ibrahim, [3] Mufida Ahmed Nagi

[1]Department of Eastern Medicine, Government College University Faisalabad-Pakistan
[2]Department of Pharmacy Technology, Higher Institute of Medical Sciences and Technologies, Bani Waleed, Libya
[3]Department of Medical Laboratory Science, College of Medical Science and Technology, Tripoli, Libya
[*]*Corresponding author:* hamza.khalifa@imst.edu.ly

Received: January 01, 2025 Accepted: January 24, 2025 Published: January 30, 2025

Abstract:

Advances in precision medicine, immunotherapy, genetics, and innovative treatment methods are propelling the fast evolution of cancer research and medication development. More individualized therapies that target certain genetic mutations and immunological pathways have replaced the one-size-fits-all strategy, giving patients fresh hope for better results and fewer side effects. The most significant developments influencing the state of cancer research and medication development are outlined in this short. Next-generation sequencing (NGS) and other techniques allow for comprehensive genomic profiling, which finds actionable mutations and directs focused treatments. Moving away from broad chemotherapy, researchers can create more potent and less harmful medicines by comprehending the distinct mutations that cause each patient's cancer. By preventing the immune system's brakes, these medications enable T cells to more successfully combat cancer cells. Nonetheless, studies are being conducted to enhance these treatments' effectiveness and safety, especially for solid tumors. Targeting certain TME elements, including the extracellular matrix or TME-resident immune cells, may offer novel treatment approaches. Large volumes of genetic data are being analyzed, possible medication candidates are being found, and patient outcomes are being predicted using AI algorithms. Additionally, machine learning models are being utilized to enhance patient stratification, optimize clinical trial design, and customize treatment regimens based on real-time data. Combination Treatments: Combination treatments that use several modes of action are becoming more and more popular due to the complexity and flexibility of cancer. To increase effectiveness and get past resistance, researchers are combining immunotherapy with targeted therapy, chemotherapy, radiation therapy, and other treatments. The objective is to prevent tumor cells from avoiding therapy by attacking cancer from several angles. These combinations are now being tested in clinical studies, which have produced encouraging findings, especially in malignancies including breast, lung, and melanoma.

Keywords*:* Precision Medicine, Gene Editing, Cancer Metabolism, Drug Resistance, Liquid Biopsy.

INTRODUCTION

With a projected 8.2 million deaths globally each year by 2030, cancer is one of the primary causes of mortality. Although our knowledge of cancer biology has expanded dramatically over the past 10 years, with many new potential disease targets appearing, the capacity to convert these discoveries into effective treatments has been restricted, with a failure rate of about 90%. The so-called "Valley of Death" in cancer treatment development becomes a very complicated issue when pharmaceutical firms' R&D expenditures decline and the cost of introducing a novel molecular entity to the market rises. This mini-review provides information on how to improve the precision and effectiveness of cancer drug development while describing curiosity-driven research and the exacting preclinical and clinical drug discovery procedures employed in industry. Since DNA is the most crucial molecule in cell reproduction and tumor cells duplicate more quickly than healthy cells, the hunt for anticancer medications has been going on for more than 50 years. Because of this, DNA is frequently the therapeutic target of anticancer medications, and the great majority of medications now in use harm DNA, which prevents cell proliferation and ultimately results in cell death. However, a new era in cancer therapy has evolved in the last 10 to 30 years, when chronic oral treatment with molecularly targeted medicines has replaced the use of cytotoxic medications and nonspecific chemotherapy in the treatment of tumors. New and contemporary treatment methods against cancer have been made possible by an understanding of the many genetic and functional biological characteristics that set tumor cells apart from healthy cells. These characteristics are referred to as the hallmarks of cancer. (1) The majority of anticancer medications are specifically designed to target particular molecular targets that have these characteristics. Ten characteristics of cancer cells, such as maintaining proliferative signals, avoiding growth suppressors, and restraining cell death, are what propel tumor development and dissemination. Numerous biopharmaceuticals, including small compounds, monoclonal antibodies, and non-antibody proteins, have been created and used to treat different kinds of cancer based on these hallmarks of target identification. Over 200 anticancer biopharmaceuticals are currently authorized, and many more are in phase I and II clinical trials or other preclinical research stages. These medications, which can be used as single agents or in combination therapies that are currently revolutionizing cancer treatment by turning some previously fatal malignancies into manageable chronic conditions, are all blatant examples of the new field of personalized medicine.



Figure 1 components of Targeted Therapy (2)

However, their long-term capacity to stabilize or cure malignant disorders is still limited by primary or secondary drug resistance, the survival of cancer stem cells, and undesirable pharmacological effects. (3) Even though taking these medications orally is linked to a higher quality of life, relapse is an almost guaranteed outcome of stopping therapy, and poor tolerability and therapeutic failure are not unusual. Additionally, the shift to targeted drugs is bringing about new paradigms in the treatment of cancer, where the growing number of oral chemotherapies is making treatment adherence a more pressing concern. (4).



Figure 2 Drug Resistance Mechanisms (5)

Targeted cancer therapy's drug resistance mechanism is closely and widely linked to tumor heterogeneity and might be a factor in the selective pressure that the therapy's melanoma cells and human lung adenocarcinoma exert cells under pharmacological stress. Here's another example: a patient with metastatic breast cancer who had was treated with its inhibitor BYL719, and the patient experienced a long-lasting clinical response. The patient, however, became resistant to this medication and passed away soon after. (6). The ability of translational studies of targeted drugs to produce more clinically relevant data is crucial because it may be used to explore resistance routes and sensible medication combinations in addition to guiding "go-go" or "no-go" choices. (7) Two distinct approaches are frequently the focus of current attempts to comprehend resistance.

Precision Medicine

With this method, doctors and researchers will be able to more precisely forecast which illness preventive and treatment plans will be effective for various populations. This is in contrast to a one-size-fits-all strategy, which develops preventative and treatment plans for the general population without taking individual characteristics into account. The idea of "precision medicine" has been a component of healthcare for many years, despite the word being relatively new. For instance, blood from a randomly chosen donor is not given to a person in need of a transfusion; To lower the chance of problems, the recipient's blood type is matched with the donors. Although there are instances in many medical specialties, precision medicine plays a comparatively small part in routine healthcare. In the upcoming years, researchers anticipate that this strategy will be applied to several facets of healthcare and health. As part of their care, patients with different kinds of cancer frequently have molecular testing done, which enables doctors to choose therapies that increase survival rates and lower the risk of side effects.



Figure 3 Workflow for Precision Diagnostics in Personalized Medicine

In order for patients and medical professionals to receive precise and clinically significant results, the FDA is trying to guarantee the accuracy of NGS testing. The FDA faces additional regulatory issues as a result of the massive volume of data provided by NGS. Even while the regulatory methods in place now are suitable for traditional diagnostics that identify a single illness or condition (such blood glucose or cholesterol levels), A single test using these new sequencing techniques is comparable to millions of tests. In order to create a flexible regulatory approach to this quickly developing technology, the FDA has worked with important industry players, labs, academic institutions, and patient and professional organizations. The FDA has also used cutting-edge open-source computing technology and consensus to support the development of NGS testing. This strategy will promote testing and research innovation and expedite the availability of precise and trustworthy genetic testing. A deeper comprehension of the molecular causes of illnesses is the foundation of precision medicine, which enables us to more accurately identify patients who will benefit from a certain course of therapy. It discusses the widespread finding that people who appear to have the same clinical diagnosis or symptoms frequently react differently to the same course of treatment. Unlike the conventional " targets therapies at the people who are most likely to benefit from them. Patient traits known as biomarkers (indicators of disease processes or therapy response) are the foundation for the capacity to focus medicines. (8)

Table 1 Comparison of Traditional Medicine vs. Precision Medicine

Aspect	Traditional Medicine	Precision Medicine
Treatment Approach	One-size-fits-all treatment for entire population	Individualized treatment based on genetic profile
Use of Genetic Information	Minimal, not commonly used for treatment decisions	Central, used to identify mutations and biomarkers
Risk of Side Effects	Higher, due to the generalized approach	Lower, as therapies are tailored to the individual’s genetic makeup
Patient Outcomes	Less predictable, based on population averages	More predictable, with treatments targeting specific genetic mutations
Regulatory Oversight	Based on established diagnostic tests	Involves complex data from Next-Generation Sequencing (NGS) tests

Gene Editing

It is a precise technique that enables researchers to remove and insert DNA into specific regions. Discussions concerning the moral and societal ramifications of human genetic engineering have been strengthened by the notable progress made in gene-editing technologies. Since the double-helix structure of DNA was discovered in the 1950s, at least, the concept of employing gene editing to heal illnesses or alter characteristics has existed. As a result of the latter's identification, there was an inevitable speculation that hereditary disorders may be avoided or reversed by finding the "molecular errors" that cause them. Although this method worked well for some scenarios, it was difficult to use and had a narrow scope. To prevent and treat human illnesses, researchers are creating gene therapies, which are medicines that include modifying the DNA. Tools for genome editing may aid in the treatment of genetically based illnesses including diabetes and cystic fibrosis. Gene treatments fall into two distinct categories both somatic and germline treatment. The DNA of reproductive cells, including sperm and eggs, is altered by germline treatments. Reproductive cell DNA alterations are inherited by subsequent generations. However, non-reproductive cells are the focus of somatic treatments, and the alterations made to these cells solely impact the individual undergoing gene therapy.



Figure 4 Comparison of CRISPR and TALEN Gene-Editing Techniques

When Layla, a one-year-old girl in the United Kingdom, got gene editing treatment in 2015 to aid her in battling leukemia, a kind of cancer, doctors successfully employed somatic gene therapy. Instead, then using CRISPR to cure Layla, these researchers used TALEN, another genome-editing technique. Genome editing is one tool that scientists employ to study many human disorders. Since they share many genes with humans, they alter the genomes of animals like zebrafish and mice. Humans and mice, for instance, have over 85% of the same genes! Scientists may study the effects of altering one or more mouse genes on the animal's health and make predictions about the potential effects of similar alterations on the human genome.

Clinical Sudie's

- CAR T-cell Therapy

A breakthrough in precision medicine, CAR T-cell therapy has shown dramatic success in treating cancers like B-cell acute lymphoblastic leukemia (ALL). One notable example is the case of Emily Whitehead, a young patient who was successfully treated with Kymriah (tisagenlecleucel) after failing conventional chemotherapy. This therapy involves genetically modifying a patient's T-cells to recognize and attack cancer cells expressing the CD19 antigen. Clinical trials have shown remarkable remission rates, demonstrating the promise of immunotherapies in treating previously untreatable cancers (10) (11).

- CRISPR-Cas9 Gene Editing

The application of CRISPR-Cas9 gene editing has revolutionized cancer research, with the technology being used to enhance T-cells' ability to target and kill cancer cells. In a clinical trial by Qasim et al. (12), T-cells were edited to knockout the PD-1 gene, a checkpoint inhibitor that reduces the immune system's ability to fight tumors. The edited T-cells showed improved efficacy in targeting and eradicating HPV-related cancers, paving the way for precision treatments using gene-editing technologies.

- Liquid Biopsy

Liquid biopsy is rapidly transforming cancer diagnosis and treatment monitoring. One of the most widely used liquid biopsy tests is Guardant360, which detects ctDNA in blood samples to identify genetic mutations associated with cancers such as non-small cell lung cancer (NSCLC). This non-invasive technique offers a way to monitor treatment efficacy and detect cancer recurrence early, without the need for invasive tissue biopsies. Studies have shown that liquid biopsies can provide critical insights into the molecular profile of a tumor and enable more personalized treatment strategies (13).

Cancer Metabolism

A developing characteristic of cancer cells is metabolic reprogramming, which enables them to withstand microenvironmental stresses and satisfy higher nutritional and energy needs. In order to adapt to various microenvironments and therapeutic treatments, cancer cells have the ability to alter their metabolic pathways. Our objective is to improve patient outcomes by deciphering the complexities of metabolic variables and creating tailored treatment methods to address unique metabolic attributes. Likewise, changes can be made to the metabolism of lipids and amino acids. Moreover, the cellular antioxidant system may be restored in cancer cells through glutamine metabolism. Because of their fast growth and elevated metabolic activity, cancer cells frequently experience oxidative stress. Glutathione, a crucial antioxidant that shields cells from oxidative damage, is produced by glutamine. Large molecules can be broken down by cancer cells to produce nutrient-free glutamine.



Figure 5 Metabolic Reprogramming in Cancer Cells [Schiliro, C., (14)]

Glutamate metabolism targeting may develop into a cutting-edge cancer therapeutic strategy. In order to combat immunological evasion, it has been discovered that blocking glutamine triggers other metabolic pathways. High-performance can quickly supply energy and raw ingredients for the synthesis of different biological macromolecules, as was previously noted. Furthermore, a significant portion is transformed into lactic acid during the aerobic process rather than going into the TCA cycle, which lowers the formation of ROS and is advantageous for the growth of tumors.

Table 2 Comparison of Metabolism in Normal vs. Cancer Cells

	Normal Cells	**Cancer Cells**
Primary Energy Source	Primarily oxidative phosphorylation (TCA cycle)	Increased glycolysis (Warburg effect)
Oxygen Consumption	Low, mainly in mitochondria	High, due to rapid energy needs and reprogramming
Glutamine Metabolism	Minimal, used for protein synthesis	High, used for energy production and antioxidant defense
Lactate Production	Low, as pyruvate enters the TCA cycle	High, lactate is produced even in the presence of oxygen
Membrane Synthesis	Low, fewer lipids required for cell division	High, to support rapid cell division and proliferation
Response to Stress	Less metabolic flexibility	Increased metabolic flexibility, especially for adapting to changing microenvironments

To sustain their activities during invasion, follower cells engage in additional metabolic processes in addition to producing energy. To preserve cell structure and function, they must manufacture substances like proteins, lipids, and nucleotides, unlike leader cells. Lipids, for instance, are essential building blocks of cell membranes, and because cancer cells divide and proliferate continuously, they must produce new membranes. These components can be obtained by follower cells through active nutrient collecting and use in the microenvironment. Additionally, follower cells have great metabolic flexibility in response to changes in their surroundings. is elevated and dysregulated in following cells, which causes a rise in the production of lipids and fatty acids. (15)

Drug Resistance

Antibiotics are ineffective. Antibiotics should only be taken as instructed and prescribed by a physician. Bacteria seize every chance to grow. They may alter (mutate) as they proliferate. The medications lose their effectiveness against the altered bacterium. Antibiotics leave resistant germs behind, but they can kill bacteria that haven't changed to withstand treatment. A bacterium's genetic composition (DNA) can occasionally mutate or alter on its own. This newly altered bacteria are not recognized by the antibiotic; thus, it is unable to combat it as it ought to. Alternatively, the alteration aids the bacteria in fending against the drug's effects. It is possible to spread a bacterial illness that is infectious and resistant to medication. Antibiotics are no longer effective in treating that person's illness. Effective therapy is typically available. However, treating resistant germs may grow increasingly challenging with time. Because it eliminates the resources used by medical personnel to treat while are ill, antibiotic resistance is concerning. Some bacteria do. This is because bacteria start to adapt as a result of the widespread use of antibiotics to treat bacterial illnesses. Consider a buddy who enjoys hosting unexpected gatherings. They may easily surprise or another member of group the first time. Maintain proper hygiene. The issue of antibiotic resistance may worsen as our civilization uses antibiotics more often. Antibiotics should only be taken when necessary. Viral infections cannot be treated with antibiotics. However, the symptoms of viral and bacterial illnesses can occasionally be identical. Obtain the vaccinations that doctor has recommended. The majority of microorganisms that cause antibiotic-resistant illnesses do not yet have vaccinations. The pneumococcal vaccination is one exception. This guards against S. pneumoniae-caused pneumococcal illness. For many populations, the vaccination is essential, particularly for individuals over 65 and children under the age of two. Other vaccinations, such as the flu shot, which guard against viral diseases, are also crucial. (16)

Liquid Biopsy

A biopsy is when a medical professional takes a sample of tissue from the tumor and examines the cells in a lab to see if they are malignant. The most reliable method for detecting cancer is a biopsy. It is the most effective method for detecting cancer. Nevertheless, when liquid biopsies identify cancer, they offer useful details about the cancerous cells that might aid a medical professional in developing a treatment strategy. Advanced cancer is known as metastatic cancer. The primary tumor location has given way to additional body sections due to metastatic cancer. Pieces of the tumor break off and enter the bloodstream as it progresses. Find out prognosis. CTCs linked to a wide range of cancer types can be found using liquid biopsies. The prognosis is better when there are fewer tumor cells than when there are more. To keep an eye on condition and modify therapy as necessary, healthcare practitioner may do routine testing.



Figure 6 Overview of the Liquid Biopsy Process

Make treatment decisions. One kind of cancer treatment called targeted therapy aims to eliminate certain cancer cell types. For instance, a particular targeted therapy may be intended to target a DNA mistake present in a cancer cell. These mistakes can be found using a liquid biopsy. Healthcare professional might not be able to reach tumor without endangering other organs, depending on its position. Which tests for liquid biopsies have FDA approval? Tests that have received FDA approval have undergone rigorous testing to guarantee accuracy and safety.

Table 3 FDA-Approved Liquid Biopsy Tests

Test Name	Manufacturer	Approved Use	Companion Diagnostic
Guardant360 CDx	Guardant Health	Comprehensive genomic profiling for advanced solid tumors.	Identifies patients eligible for targeted therapies, including osimertinib for non-small cell lung cancer.
FoundationOne Liquid CDx	Foundation Medicine	Comprehensive genomic profiling for advanced solid tumors.	Assists in identifying patients suitable for therapies such as erlotinib, gefitinib, and osimertinib for non-small cell lung cancer.
Shield	Guardant Health	Screening for colorectal cancer in individuals aged 45 and older.	N/A

There are a number of liquid biopsy tests under development and in different phases of study. The FDA has authorized four of them: CTCs are detected by the test. It is used to forecast the probable outcome for patients with colon, prostate, or breast cancer that has spread. It might assist physician in keeping an eye on health. A prognosis is indicated by a small number of CTCs in the blood. A bad prognosis is indicated by a high blood level of CTCs. Physicians at the University of Chicago Medicine are using liquid biopsies more frequently. This new method uses a straightforward blood test rather than an invasive needle procedure to find indications of malignant tumors. Oncologists at the University of Chicago Medicine see potential in this quicker, safer, and more efficient test, even though needle biopsy is still the gold standard for both assessing a patient's genetic makeup and diagnosing cancer. This is especially true for patients with metastatic cancers who need multiple biopsies both during and after treatment. Dr. Ari Rosenberg, an oncologist at the University of Chicago Medicine who specializes in head, neck, and thyroid malignancies, stated that liquid biopsies can be used to gauge a patient's reaction to therapy and even direct real-time de-escalation. Most cancers release DNA into the circulation as they spread. Compared to a needle biopsy, which frequently requires an ultrasound or CT scan and, in some situations, a blood test is more practical and less costly. Another significant advantage of liquid biopsies is that they yield answers in around a week, which is two to three times quicker than using tissue biopsies to collect genetic information, according to Dr. Christine, a thoracic oncologist at It assists in locating additional individuals who could profit from tailored medication. Turnaround time is crucial when it comes to cancer. However, not every patient is a good candidate for liquid biopsies. Certain people have distinct DNA that might distort test findings and raise the risk of false positives. Furthermore, a follow-up liquid biopsy may be necessary if any malignancy is found. (12) (17)

Challenges and Limitations in Cancer Research and Treatment

Despite notable advances in cancer research and the development of innovative treatments, many challenges continue to hinder progress in the fight against cancer. One of the main obstacles is the emergence of drug resistance. While targeted therapies and immunotherapies have significantly improved treatment outcomes for many patients, resistance to these therapies often develops over time. Genetic mutations, changes in the tumor microenvironment (TME), or the presence of cancer stem cells can lead to resistance to Medications. For example, BRAF inhibitors used in the treatment of melanoma often lead to the development of resistance through secondary mutations in the MAPK pathway, highlighting the need for ongoing research into combination therapies and more effective ways to overcome tumor evasion mechanisms (18).

Another major challenge is the high cost of treatment. The development of precision medicine and immunotherapy has led to groundbreaking treatments, but these treatments come at high costs. For example, CAR T-cell therapies can exceed $373,000 per patient, and the long-term costs associated with ongoing treatments, monitoring, and follow-up care are significant. These high costs often limit access to life-saving treatments, particularly in low- and middle-income countries. This disparity in access emphasizes the need to better healthcare policies, insurance coverage, and efforts to reduce the cost of advanced cancer treatments (19).

In addition, the ethical and regulatory concerns surrounding gene-editing technologies such as CRISPR-Cas9 complicate their widespread adoption. While gene editing holds tremendous potential in cancer treatment, it raises ethical issues, particularly around germ lineage, which can alter the DNA of embryos or reproductive cells and possibly affect future generations. Although somatic genetic modification, which targets only the patient's cells, is acceptable on Widespread scope, however, long-term safety and potential unintended consequences remain a concern. Furthermore, ethical debates about equity and consent, especially for vulnerable populations, must be addressed to ensure that these technologies are used responsibly and fairly (20).

Limited access and global disparities in cancer care are additional challenges. Many low- and middle-income countries face significant barriers in accessing advanced cancer treatments, diagnostic tools, and genotyping. These areas often lack the infrastructure for cutting-edge research and clinical trials, resulting in delayed diagnosis and unfair treatment outcomes. To overcome these disparities, there is a need to improve healthcare infrastructure, and increase funding for cancer research in the regions underrepresented, promoting international cooperation to ensure that advances in cancer care reach the entire population, regardless of their socioeconomic status (21).

These challenges underscore the complexities involved in translating scientific innovations into effective, equitable and accessible cancer treatments. Addressing these barriers requires ongoing research, collaboration across disciplines, and global efforts to ensure that all patients benefit advances in cancer treatment. (22)

Future Trends in Cancer Treatment

While many challenges remain, the future of cancer treatment is full of promise. Continuous advances in precision medicine, immunotherapy, and gene-editing techniques have the potential to significantly improve patient outcomes. However, these technologies must be adapted for a broader application, with a greater focus on affordability, accessibility and long-term safety.

Artificial intelligence and machine learning are poised to revolutionize cancer research by enabling faster and more accurate diagnostics, patient stratification, and the discovery of new drug targets. In addition, nanomedicine and cancer vaccines are promising areas of research that could lead to the development of more effective and personalized cancer treatments.

Ultimately, the future of cancer treatment lies in integrated and personalized care that combines the latest advances in biotechnology, pharmacology and clinical practice. With continuous research, collaboration and innovation, we may soon see a world where cancer is no longer a fatal disease but a manageable condition.

Conclusion

Innovations in precision medicine, immunotherapy, genetic profiling, and new treatment methods are revolutionizing the field of cancer research and medication development. The move toward individualized therapies that are catered to the genetic composition of each patient holds promise for greatly increasing therapeutic effectiveness while reducing adverse effects. Immunotherapies, such CAR T-cell treatments and immune checkpoint inhibitors, are showing previously unheard-of efficacy in treating some types of cancer, and research is being done to extend its use to a wider variety of tumors. Additionally, developments in liquid biopsy-based early detection, together with the exciting possibilities of gene editing, cancer vaccinations, and nanomedicine, have the potential to completely transform how we approach diagnosis and therapy. Even while these developments show promise, there are still issues to be resolved, such overcoming drug resistance, increasing access to innovative medicines, and making sure that cancer treatments are customized for a wider range of cancer types. However, advancements in clinical trials, drug development, and individualized treatment plans are being accelerated by the confluence cancer therapy appears brighter as research keeps pushing the limits of science, perhaps leading to more effective medications and, eventually, a world where cancer is a disease that can be managed or even cured.

References

[1] Compton C, Compton C. Understanding the hallmark characteristics of cancer. Cancer: The Enemy from Within: A Comprehensive Textbook of Cancer’s Causes, Complexities and Consequences. 2020:49-81.

[2] Wu, H. C., Chang, D. K., & Huang, C. T. (2006). Targeted therapy for cancer. J Cancer Mol, 2(2), 57-66.

[3] Dragu DL, Necula LG, Bleotu C, Diaconu CC, Chivu-Economescu M. Therapies targeting cancer stem cells: Current trends and future challenges. World journal of stem cells. 2015 Oct 26;7(9):1185.

[4] Foulon V, Schöffski P, Wolter P. Patient adherence to oral anticancer drugs: an emerging issue in modern oncology. Acta Clinica Belgica. 2011 Apr 1;66(2):85-96.

[5] Dai, Z., Gu, X. Y., Xiang, S. Y., Gong, D. D., Man, C. F., & Fan, Y. (2020). Research and application of single-cell sequencing in tumor heterogeneity and drug resistance of circulating tumor cells. *Biomarker research*, *8*, 1-8.

[6] Little SJ, Holte S, Routy JP, Daar ES, Markowitz M, Collier AC, Koup RA, Mellors JW, Connick E, Conway B, Kilby M. Antiretroviral-drug resistance among patients recently infected with HIV. New England Journal of Medicine. 2002 Aug 8;347(6):385-94.

[7] Neville V, Nakagawa S, Zidar J, Paul ES, Lagisz M, Bateson M, Løvlie H, Mendl M. Pharmacological manipulations of judgement bias: A systematic review and meta-analysis. Neuroscience & Biobehavioral Reviews. 2020 Jan 1; 108:269-86.

[8] Mirnezami R, Nicholson J, Darzi A. Preparing for precision medicine. N Engl J Med. 2012 Feb 9;366(6):489-91.
[9] Gaj T, Sirk SJ, Shui SL, Liu J. Genome-editing technologies: principles and applications. Cold Spring Harbor perspectives in biology. 2016 Dec 1;8(12): a023754.
[10] Maude, S. L., et al. (2018). Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia. New England Journal of Medicine, 378(5), 449-459.
[11] Lee, D. W., et al. (2014). T Cells Modified with a Chimeric Antigen Receptor in Acute Lymphoblastic Leukemia. New England Journal of Medicine, 371(16), 1507-1517.
[12] Qasim, W., et al. (2018). CRISPR-Cas9 Gene Editing of T Cells to Target Cancer. Nature Biotechnology, 36(5), 404-412.
[13] Ignatiadis M, Sledge GW, Jeffrey SS. Liquid biopsy enters the clinic—implementation issues and future challenges. Nature reviews Clinical oncology. 2021 May;18(5):297-312.
[14] Schiliro, C., & Firestein, B. L. (2021). Mechanisms of metabolic reprogramming in cancer cells supporting enhanced growth and proliferation. Cells, 10(5), 1056.
[15] Martinez-Outschoorn UE, Peiris-Pagés M, Pestell RG, Sotgia F, Lisanti MP. Cancer metabolism: a therapeutic perspective. Nature reviews Clinical oncology. 2017 Jan;14(1):11-31.
[16] Longley DB, Johnston PG. Molecular mechanisms of drug resistance. The Journal of Pathology: A Journal of the Pathological Society of Great Britain and Ireland. 2005 Jan;205(2):275-92.
[17] Ashuor, A. A. A., Bukhres, M. B., & Omar, W. A. S. (2025). Multifaceted Approaches in Breast Cancer Care: Insights from Research and Clinical Practice. Libyan Journal of Medical and Applied Sciences, 22-32. [18] Scott, D. A., & Borrelli, L. A. (2019). Cost of CAR T-cell therapy: A review of the economics of CAR T-cell therapy for cancer treatment. Journal of Clinical Oncology, 37(31), 2776-2781.
[19] Doudna, J. A., & Charpentier, E. (2014). The new frontier of genome engineering with CRISPR-Cas9. Science, 346(6213), 1258096.
[20] Bray, F., et al. (2018). Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians, 68(6), 394-424.
[21] Mathai, R. A., Reddy, B. S., & Rao, M. (2019). Potential Utility of Liquid Biopsy as a Diagnostic and Prognostic Tool for the Assessment of Solid Tumors: Implications in Precision Oncology. Journal of Clinical Medicine, 8(3), 325.
[21] Ibrahim, H. K., miftah Almahtout, A., & Khalefa, E. M. Multifaceted Approaches in Breast Cancer Care: Insights From Research and Clinical Practice. Global Journal of Agricultural and Biological Sciences, 1(1), 53-75.